



# Supplementary Figure 1




**Figure S1. Myeloid-biased HSCs increase with aging.** (A-B) BM of 2-3 month- or 22-24 month-old mice was analyzed for My-(lower-SP<sup>KLS-CD150+</sup>) and Ly-bi HSCs (upper-SP<sup>KLS-CD150+</sup>). Top panel demonstrates delineation of SP gate. From SP sample gate KLS cells were identified, followed by the CD150<sup>+</sup> fraction, followed by analysis of lower- and upper-SP phenotypes. Representative FACS profiles of lower- and upper-SP<sup>KLS-CD150+</sup> HSCs from young and old mice. (C) Frequencies of lower- and upper-SP<sup>KLS-CD150+</sup> cells from young and old mice (n=5 Young, n=5 Old). Error bars represent SEM. Representative of 2 experiments.

# Supplementary Figure 2

A




B




**Figure S2. Effect of overexpression of Rantes on PB populations.** (A) Representative PB lineage analyses of mice transplanted with control MSCV (GFP- transduced) or Rantes transduced (Rantes+ GFP) bone marrow cells 12 weeks after transplantation. Representative FACS profiles of lineages (Myeloid, B- cells and T-cells) within the donor-derived GFP+ cells in GFP-only or Rantes-GFP overexpressing mouse. (B) The graph represents the lineage distribution (Myeloid, B- cells, and T-cells) of GFP+ donor-derived white blood cells of mice transplanted with GFP-only or Rantes-GFP-transduced cells 16 weeks after transplantation (n=10). Error bars represent SEM.

# Supplementary Figure 3




**Figure S3. Effect of ex-vivo treatment of stem cells with Rantes/Ccl5 before transplantation.** (A) Peripheral blood lineage analyses of mice transplanted with stem cells that are either un-treated or Rantes-treated ex-vivo before transplantation. Representative FACS profiles of lineage distribution of donor derived (CD45.2<sup>+</sup>) white blood cells 16 weeks after transplantation. (B) Representative FACS profiles of BM frequencies of donor-derived myeloid progenitors in BM from mice transplanted with Rantes-treated or un-treated HSCs (SP<sup>KLS</sup>) in a competitive transplantation. 5 months after-transplantation, HSC-derived progenitors was analyzed as follows, CMP: Lin<sup>-</sup>, Sca-1<sup>-</sup>, IL7 $\alpha$ <sup>-</sup>, c-Kit<sup>+</sup>, CD45.2<sup>+</sup>, Fc $\gamma$ R<sup>lo</sup> CD34<sup>+</sup>; GMP: Lin<sup>-</sup> Sca-1<sup>-</sup>, IL7 $\alpha$ <sup>-</sup>, c-Kit<sup>+</sup>, CD45.2<sup>+</sup>, Fc $\gamma$ R<sup>+</sup> CD34<sup>+</sup>; MEP: Lin<sup>-</sup>, Sca-1<sup>-</sup>, IL7 $\alpha$ <sup>-</sup>, c-Kit<sup>+</sup>, CD45.2<sup>+</sup>, Fc $\gamma$ R<sup>-</sup> CD34<sup>-</sup> (n=7 Untreated, n=7 Rantes).

## Supplementary Figure 4




**Figure S4. Effect of ex-vivo treatment of stem cells with Rantes/Ccl5 before transplantation.** Representative FACS profiles of BM frequencies of donor-derived common lymphoid progenitors in BM from mice transplanted with Rantes-treated or untreated HSCs (SP<sup>KLS</sup>) in a competitive transplantation. 5 months after-transplantation, HSC-derived CLPs were analyzed as follows : Lin<sup>-</sup>, IL7 $\alpha$ <sup>+</sup>, c-Kit<sup>lo</sup>, Flt3<sup>+</sup>, Sca-1<sup>lo</sup> (n=7 untreated n=7 Rantes).

## Supplementary Figure 5



**Figure S5. Absolute numbers of progenitor/stem cells in KO mice.** (A) Graph represents absolute numbers of common myeloid progenitors (GMP, CMP and MEP) from 5-6 month-old WT and KO mice (n=5 WT, n=5 KO). (B) Frequencies of common lymphoid progenitors (CLP) from 5-6 month-old WT and KO mice (n=5 WT, n=5 KO). (C) Graph represents absolute numbers of CLPs from 5-6 month-old WT and KO mice (n=5 WT, n=5 KO). (D) Absolute numbers of KLS, SP-KLS cells from 5-6 month-old WT and KO mice (n=5 WT, n=5 KO).

## Supplementary Figure 6



**Figure S5. Expression of pro-lymphoid genes increase in KO mice.** Quantitative real-time PCR analysis of Gata2, Gata3 and Ikaros on mRNA purified from WT and KO HSCs ( $SP^{KLS-CD150+}$ ) (n=3 WT, n=3 KO). Error bars represent SEM.